Microbiota and prostate cancer.
Genitourinary cancers
Genitourinary microbiome
Microbiome
Microbiota
Prostate cancer
Journal
Seminars in cancer biology
ISSN: 1096-3650
Titre abrégé: Semin Cancer Biol
Pays: England
ID NLM: 9010218
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
12
04
2021
revised:
10
09
2021
accepted:
11
09
2021
pubmed:
19
9
2021
medline:
23
11
2022
entrez:
18
9
2021
Statut:
ppublish
Résumé
Prostate cancer remains the most frequently diagnosed non-skin malignancy in male patients, still representing one of the main causes of cancer-related death worldwide. Evidence is mounting that suggests the putative role of microbiota in the carcinogenesis as well as in modulating the efficacy and activity of anticancer treatments (e.g., chemotherapy, immune checkpoint inhibitors, targeted therapies) in a large number of hematological and solid tumors. However, few data are available regarding the interactions between prostate cancer and microbiome so far, in particular in terms of the impact of microbiota on disease development, pathogenesis, and response to medical treatments in this genitourinary malignancy. Herein, we provide an overview of current knowledge, novel insights and emerging therapeutic approaches related to gastrointestinal and genitourinary microbiome in prostate cancer patients, especially focusing on available evidence and published trials on this topic.
Identifiants
pubmed: 34536504
pii: S1044-579X(21)00230-3
doi: 10.1016/j.semcancer.2021.09.007
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1058-1065Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest All authors declare that they have no conflicts of interest